What are the clinical features, prognosis, and recommended management for trisomy 14?

Trisomy 14: Clinical Features, Prognosis, and Management

Critical Clarification

Trisomy 14 is NOT compatible with life in its complete form—only mosaic trisomy 14 (where some cells have three copies of chromosome 14 and others are normal) occurs in liveborn infants. This is fundamentally different from trisomy 13 and trisomy 18, which can occur in complete forms in liveborns. The provided guidelines address trisomy 13/18, not trisomy 14, and should not be applied to trisomy 14 cases.

Clinical Features of Mosaic Trisomy 14

Mosaic trisomy 14 presents with a constellation of findings that vary based on the percentage and tissue distribution of trisomic cells 1, 2, 3:

Core Clinical Manifestations

• Growth abnormalities: Intrauterine growth restriction, postnatal short stature, and failure to thrive
• Craniofacial dysmorphism: Microcephaly, broad nose, wide mouth, high or cleft palate, micrognathia, hypertelorism, low-set small ears
• Neurological: Developmental delay, hypotonia, mental retardation (severity correlates with mosaicism level)
• Cardiac: Congenital heart disease (including double outlet right ventricle, ventricular septal defects, pulmonary stenosis) 4
• Musculoskeletal: Limb length asymmetry, talipes equinovarus, developmental asymmetry
• Dermatologic: Linear-whorl distribution of abnormal pigmentation (hyperpigmented linear spots) 2, 3
• Other: Cryptorchidism, macroglossia, hepatic involvement (neonatal hepatitis) 2

Prognosis

Prognosis is directly proportional to the level of mosaicism and tissue distribution of the trisomic cell line:

Favorable Outcomes

Low-level mosaicism (<15% in blood) can be associated with:

• Normal phenotype and development 5
• Progressive perinatal decrease of the trisomy 14 cell line
• Favorable fetal outcomes when confined to placenta or when present at very low levels

Poor Outcomes

High-level mosaicism (>40% in amniocytes) is associated with:

• Severe congenital heart defects
• Intrauterine growth restriction
• Facial dysmorphism
• High risk of pregnancy loss or termination 4

Critical caveat: The phenotype can range from near-normal to severe multiple congenital anomalies depending on which tissues harbor the trisomic cells and at what percentage 3.

Recommended Management

Prenatal Period

When mosaic trisomy 14 is detected prenatally:

1. Confirm the diagnosis and assess mosaicism level:

   • Perform both cultured and uncultured amniocyte analysis (cytogenetic discrepancies can occur) 5
   • Array CGH on uncultured amniocytes to quantify mosaicism percentage
   • Consider repeat amniocentesis if initial mosaicism is borderline, as levels may decrease 5

2. Rule out uniparental disomy (UPD) 14:

   • Perform polymorphic marker analysis or methylation-specific PCR of the MEG3 promoter
   • UPD14 carries distinct clinical implications (Temple syndrome for maternal UPD14, Kagami-Ogata syndrome for paternal UPD14) 2, 3

3. Detailed anatomic survey:

   • Focus on cardiac anatomy (echocardiography for structural defects)
   • Monitor growth parameters serially for IUGR
   • Assess for other structural anomalies

4. Parental counseling:

   • Explain the wide phenotypic spectrum based on mosaicism level
   • Low-level mosaicism (<15%) may have normal outcomes
   • High-level mosaicism (>40%) carries significant risk of anomalies
   • Offer pregnancy termination as an option for high-level mosaicism with structural defects

Postnatal Period

For liveborn infants with confirmed mosaic trisomy 14:

1. Immediate neonatal assessment:

   • Complete physical examination documenting dysmorphic features
   • Echocardiography (congenital heart disease is common)
   • Renal ultrasound (genitourinary anomalies)
   • Karyotype analysis on multiple tissues (blood, skin fibroblasts, buccal cells) to determine tissue distribution 3

2. Ongoing surveillance:

   • Growth monitoring (height, weight, head circumference)
   • Developmental assessments at regular intervals
   • Cardiac follow-up based on initial findings
   • Monitor for hepatic dysfunction (liver function tests if hepatomegaly or jaundice)
   • Ophthalmologic and audiology evaluations
   • Orthopedic assessment for limb asymmetry or skeletal anomalies

3. Supportive interventions:

   • Early intervention services for developmental delays
   • Physical and occupational therapy for hypotonia
   • Surgical correction of cardiac defects, cleft palate, or other structural anomalies as indicated
   • Nutritional support for failure to thrive

Key Pitfalls to Avoid

• Do not confuse mosaic trisomy 14 with trisomy 13/18: The management paradigms differ significantly; trisomy 14 is only viable in mosaic form
• Do not rely solely on cultured amniocytes: Cytogenetic discrepancies between cultured and uncultured cells are documented 5
• Do not overlook UPD14 testing: This has distinct clinical implications separate from the mosaicism itself
• Do not assume uniform prognosis: The percentage and tissue distribution of trisomic cells determines outcomes—low-level mosaicism can have normal outcomes 5
• Do not miss progressive decrease in mosaicism: Serial testing may show declining percentages of trisomic cells perinatally 5